Related Experiment Video

Updated: Jun 9, 2026

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats
04:12

Modeling Posthemorrhagic Hydrocephalus of Prematurity in Rats

Published on: March 28, 2025

Propranolol as first-line treatment for rapidly proliferating infantile haemangiomas

W J M Holmes1, A Mishra, C Gorst

  • 1Department of Plastic Surgery, Alder Hey Children's Hospital, Eaton Road, Liverpool L12 2AP, UK. willjmholmes@googlemail.com

Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS
|August 28, 2010
PubMed

Insights

Propranolol effectively halts infantile haemangioma proliferation and induces regression in most cases. This study supports propranolol as a well-tolerated first-line treatment for problematic infantile haemangiomas.

Area of Science:

  • Pediatric Oncology
  • Dermatology
  • Pharmacology

Background:

  • Infantile haemangioma is the most common childhood tumor, with about 10% requiring intervention.
  • Recent studies indicate propranolol's high efficacy in treating rapidly proliferating haemangiomas.

Purpose of the Study:

  • To prospectively evaluate propranolol's effectiveness as a first-line therapy for problematic infantile haemangiomas.
  • To establish a standardized treatment protocol for propranolol administration.

Main Methods:

  • 31 consecutive patients with rapidly proliferating infantile haemangioma causing functional impairment or cosmetic issues were enrolled.
  • All patients underwent cardiovascular pre-treatment assessment and were initiated on propranolol at 3 mg/kg/day.
  • The study prospectively monitored treatment response and side effects.

Main Results:

  • 100% of patients experienced an immediate cessation of haemangioma proliferation.
  • Significant regression of haemangioma was observed in 87% of patients.
  • Propranolol treatment was well-tolerated with minimal adverse effects.

Conclusions:

  • Propranolol demonstrates remarkable efficacy and safety as a first-line treatment for problematic infantile haemangiomas.
  • The study's findings led to the adoption of propranolol as a standard first-line therapy for such cases in the unit.
  • This approach offers a promising therapeutic option for infantile haemangioma management.

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...